The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case-control study

Pharmacopsychiatry

Volumn 40, Issue 3, 2007, Pages 111-115

  Stolk, P ^a   Souverein, P C ^a   Leufkens, H G M ^a   Weil, J G ^b   Egberts, A C G ^a   Heerdink, E R ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

COX 2 inhibitors; Pharmacoepidemiology; Schizophrenia

Indexed keywords

ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIPARKINSON AGENT; CARDIAC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOLYTIC ADENOVIRUS; TRANQUILIZER;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EXPOSURE; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL ANALYSIS;

AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SEX FACTORS; TIME FACTORS;

EID: 34250360765     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-977714     Document Type: Article

References (13)

1. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90: 179-185
2. Bresee CJ, Delrahim K, Maddux RE, Dolnak D, Ahmadpour O, Rapaport MH. The effects of celecoxib augmentation on cytokine levels in schizophrenia. Int J Neuropsychopharmacol 2006; 9: 343-348
3. Doux JD, Bazar KA, Lee PY, Yun AJ. Can chronic use of anti-inflammatory agents paradoxically promote chronic inflammation through compensatory host response. Med Hypotheses 2005; 65: 389-391
4. Hoffman C. COX-2 in brain and spinal cord - implications for therapeutic use. Curr Med Chem 2000; 7: 1113-1120
5. Hugenholtz GW, Heerdink ER, Meijer WE, Stolker JJ, Egberts AC, Nolen WA. Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 2005; 38: 122-124
6. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159: 1029-1034
7. Müller N, Riedel M, Schwarz MJ. Psychotropic effects of COX-2 inhibitors - possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 2004; 37: 266-269
8. Müller N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005; 255: 149-151
9. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680-684
10. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackeheil M, Möller, Gruber R, Riedel M. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Clin Neurosci 2004; 254: 14-22
11. Onder G, Pellicciotti F, Gambassi G, Bernabei R. NSAID-related psychiatric adverse events: who is at risk? Drugs 2004; 64: 2619-2627
12. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005; 57: 1594-1596
13. Riedel M, Strassnig M, Schwarz MJ, Mueller N. COX-2 inhibitors as adjunctive therapy in schozphrenia - rationale for use and evidence to date. CNS Drugs 2005; 19: 805-819